Kristin Stephens's most recent trade in Syros Pharmaceuticals Inc. was a trade of 36,133 Common Stock done at an average price of $0.2 . Disclosure was reported to the exchange on Nov. 18, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Sale of securities on an exchange or to another person at price $ 0.22 per share. | 18 Nov 2024 | 36,133 | 0 (0%) | 0% | 0.2 | 7,949 | Common Stock |
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 17,000 | 42,237 (0%) | 0% | - | Common Stock | |
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2024 | 17,000 | 0 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.09 per share. | 31 Oct 2024 | 6,104 | 36,133 (0%) | 0% | 2.1 | 12,757 | Common Stock |
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 11,666 | 23,334 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 11,666 | 29,455 (0%) | 0% | - | Common Stock | |
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.12 per share. | 31 Mar 2024 | 4,218 | 25,237 (0%) | 0% | 5.1 | 21,596 | Common Stock |
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2024 | 2,000 | 17,789 (0%) | 0% | - | Common Stock | |
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,000 | 5,088 (0%) | 0% | - | Common Stock | |
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2023 | 2,000 | 6,000 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.58 per share. | 31 Mar 2023 | 623 | 4,465 (0%) | 0% | 2.6 | 1,607 | Common Stock |
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 35,000 | 35,000 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 44,500 | 44,500 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Oct 2022 | 34,000 | 34,000 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.12 per share. | 01 Apr 2022 | 14,115 | 30,885 (0%) | 0% | 1.1 | 15,809 | Common Stock |
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 200,000 | 200,000 | - | - | Restricted Stock Units | |
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Syros Pharmaceuticals Inc. | Kristin Stephens | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 80,000 | 80,000 | - | - | Restricted Stock Units |